These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24025258)

  • 1. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
    Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
    Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceramide in the prostate.
    Dent P
    Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.
    Mukhopadhyay A; Saddoughi SA; Song P; Sultan I; Ponnusamy S; Senkal CE; Snook CF; Arnold HK; Sears RC; Hannun YA; Ogretmen B
    FASEB J; 2009 Mar; 23(3):751-63. PubMed ID: 19028839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
    Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
    Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
    Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
    J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells.
    Kim SW; Kim HJ; Chun YJ; Kim MY
    J Toxicol Environ Health A; 2010; 73(21-22):1465-76. PubMed ID: 20954073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
    Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney.
    Li M; Guo H; Damuni Z
    Biochemistry; 1995 Feb; 34(6):1988-96. PubMed ID: 7531497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
    Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
    Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lentivirus-mediated silencing of I2PP2A through RNA interference attenuates trichloroethylene-induced cytotoxicity in human hepatic L-02 cells.
    Yang X; Jiang Y; Li J; Hong WX; Wu D; Huang X; Huang H; Zhou L; Yang L; Yuan J; Zhuang Z; Liu J
    Toxicol Lett; 2012 Mar; 209(3):232-8. PubMed ID: 22245669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
    Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
    Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
    Dacol EC; Wang S; Chen Y; Lepique AP
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
    Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
    Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
    Bhardwaj A; Singh S; Srivastava SK; Honkanen RE; Reed E; Singh AP
    Mol Cancer Ther; 2011 May; 10(5):720-31. PubMed ID: 21393425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of protein phosphatase 2A activity by PI3Kγ regulates β-adrenergic receptor function.
    Vasudevan NT; Mohan ML; Gupta MK; Hussain AK; Naga Prasad SV
    Mol Cell; 2011 Mar; 41(6):636-48. PubMed ID: 21419339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
    Switzer CH; Cheng RY; Vitek TM; Christensen DJ; Wink DA; Vitek MP
    Oncogene; 2011 Jun; 30(22):2504-13. PubMed ID: 21297667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal ceroid lipofuscinosis related ER membrane protein CLN8 regulates PP2A activity and ceramide levels.
    Adhikari B; De Silva B; Molina JA; Allen A; Peck SH; Lee SY
    Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):322-328. PubMed ID: 30453012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
    Enjoji S; Yabe R; Tsuji S; Yoshimura K; Kawasaki H; Sakurai M; Sakai Y; Takenouchi H; Yoshino S; Hazama S; Nagano H; Oshima H; Oshima M; Vitek MP; Matsuura T; Hippo Y; Usui T; Ohama T; Sato K
    Mol Cancer Res; 2018 Mar; 16(3):554-563. PubMed ID: 29330298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.